SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Enanta Pharmaceuticals (ENTA)

ENTA RSS Feed
Add ENTA Price Alert      Hide Sticky   Hide Intro
Moderator: DewDiligence
Search This Board:
Last Post: 12/9/2016 4:18:31 PM - Followers: 61 - Board type: Free - Posts Today: 0
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ENTA
Current Price
Volume:
Bid Ask Day's Range
SureTrader
ENTA News: Securities Registration: Employee Benefit Plan (s-8) 12/09/2016 04:12:38 PM
ENTA News: Annual Report (10-k) 12/09/2016 04:09:38 PM
ENTA News: Amended Statement of Ownership (sc 13g/a) 12/09/2016 12:43:48 PM
ENTA News: Statement of Changes in Beneficial Ownership (4) 11/30/2016 05:01:19 PM
ENTA News: Amended Statement of Changes in Beneficial Ownership (4/a) 11/22/2016 06:46:41 PM
News News Alert: Securities Registration: Employee Benefit Plan (s-8) 12/09/2016 04:12:38 PM
PostSubject
#1426  Sticky Note ENTA could earn $9.50/sh in 2020: #msg-126723412. DewDiligence 11/21/16 08:09:57 PM
#1433   The FY2016 10-K has been filed: DewDiligence 12/09/16 04:18:31 PM
#1432   BlackRock upped its stake to 10.4% on 11/30/16 DewDiligence 12/09/16 01:07:15 PM
#1431   GILD submits NDA for SOF/VEL/VOX HCV regimen: #msg-127098862. DewDiligence 12/08/16 10:17:53 AM
#1430   Enanta in HCV. Here are the 3 main willyw 11/25/16 09:59:53 AM
#1429   Model assumptions: 30% G/P market share; pricing similar DewDiligence 11/22/16 02:13:34 PM
#1428   What pricing and market share assumptions did you nowlurking 11/22/16 02:09:08 PM
#1427   ENTA appoints former TEVA executive to BoD: #msg-126730864. DewDiligence 11/22/16 08:51:19 AM
#1426   ENTA could earn $9.50/sh in 2020: #msg-126723412. DewDiligence 11/21/16 08:09:57 PM
#1425   ENTA's enterprise value is cheap: #msg-126720919. DewDiligence 11/21/16 05:34:25 PM
#1424   FY4Q16 financial results/cash balance: #msg-126720369. DewDiligence 11/21/16 05:33:18 PM
#1422   I just saw on twitter that ENTA has willyw 11/17/16 11:13:04 AM
#1421   Late breaker presentation 2nd gen G/P willyw 11/17/16 09:14:26 AM
#1420   Hep B has proven to be a tough willyw 11/16/16 08:43:40 AM
#1419   Hey this stuff also works on HepB right linhdtu 11/15/16 10:13:51 PM
#1418   I posted the EXPEDITION-4 results in #msg-126567102 (same PR). DewDiligence 11/15/16 12:05:10 PM
#1417   Enanta Pharmaceuticals Announces AbbVie’s Investigational, Pan-Genotypic Regimen of willyw 11/15/16 08:38:32 AM
#1416   More G-3 data from AASLD willyw 11/15/16 07:02:38 AM
#1415   EDP 494 Enta's cyclophilin inhibitor willyw 11/13/16 11:39:14 PM
#1414   http://www.aasld.org/sites/default/files/2016-AbstractSupplement-TheLiverMeeting willyw 11/13/16 11:38:30 PM
#1413   The renal impairment trial results- late breaker willyw 11/13/16 11:22:52 AM
#1412   Comparing Abbvie's 2nd gen(G/P) to Gilead's triple. willyw 11/13/16 10:52:43 AM
#1411   MRK’s 3-DAA HCV regimen fails to impress: #msg-126517784. DewDiligence 11/13/16 10:43:49 AM
#1410   ENTA presents preclinical data for NASH compound, EDP-305 DewDiligence 11/11/16 08:56:27 AM
#1409   ABBV/ENTA report 8w Glecaprevir/Pibrentasvir phase-3 data from three trials: DewDiligence 11/11/16 08:47:32 AM
#1408   ENTA new slide deck: DewDiligence 11/07/16 03:59:59 PM
#1407   3Q16 Viekira sales $378M, -10% QoQ: #msg-126121950. DewDiligence 10/28/16 08:04:22 AM
#1406   Musings on GILD’s POLARIS studies of 3-DAA HCV regimen: DewDiligence 10/20/16 12:21:42 PM
#1405   Second generation direct-acting antivirals – Do we expect willyw 10/08/16 06:52:32 AM
#1404   ENTA-related excerpts from C&EN NASH article: #msg-125551256. DewDiligence 10/03/16 04:00:46 PM
#1403   Per the AASLD abstracts, I am seeing high willyw 10/03/16 09:47:29 AM
#1399   ABBV/ENTA's second-generation HCV regimen gets FDA BTD for DewDiligence 09/30/16 08:19:47 AM
#1398   ENTA presents ex-vivo data on lead RSV candidate: DewDiligence 09/29/16 04:16:21 PM
#1397   ENTA starts phase-1 trial of EDP-305: #msg-125454754. DewDiligence 09/28/16 04:28:09 PM
#1396   First 8-week V-Pak data shows 98% SVR12 in DewDiligence 09/23/16 09:14:46 AM
#1395   Slide set from Morgan Stanley webcast on 9/12/16: DewDiligence 09/20/16 04:40:20 PM
#1394   Baird Q&A presentation nowlurking 09/08/16 01:17:42 PM
#1393   The FY3Q16 10-Q has been filed: DewDiligence 08/09/16 04:22:35 PM
#1392   Yup; I've seen it in two forums. 3 willyw 08/08/16 11:11:12 PM
#1391   I don't follow it either; I'm just reporting willyw 08/08/16 10:29:43 PM
#1390   I don't understand why ABT-493/ABT-530 would consist of DewDiligence 08/08/16 10:22:00 PM
#1389   Ah Good! I'm half surprised. They have really willyw 08/08/16 10:15:59 PM
#1388   …does [ENTA’s royalty] formula combine sales of 1st- DewDiligence 08/08/16 09:46:20 PM
#1387   Rocky wrote; with the overall HCV market going willyw 08/08/16 08:04:45 PM
#1386   The higher royalty payments will be meaningful if DewDiligence 08/08/16 06:41:10 PM
#1385   Milestone payments will make it even more like Rocky3 08/08/16 06:38:18 PM
#1384   $80M of milestone payments are coming for next-gen DewDiligence 08/08/16 05:23:31 PM
#1383   "Revenue for the three months ended June 30, biotech_researcher 08/08/16 05:21:51 PM
#1382   ENTA had $244.7M of cash at 6/30/16, a DewDiligence 08/08/16 04:10:32 PM
#1381   Viekira sales by calendar quarter: #msg-124189583. DewDiligence 07/29/16 09:24:42 AM
#1380   1. Why hasn't ABBV been able to sell DewDiligence 07/26/16 09:48:40 AM
PostSubject